Abstract
The stability of mRNA is one of the key factors governing the regulation of eukaryotic gene expression and function. Human antigen R (HuR) is an RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm shuttling of its target mRNAs. While HuR is normally localized within the nucleus, it has been shown that HuR binds mRNAs in the nucleus and then escorts the mRNAs to the cytoplasm where HuR protects them from degradation. It contains several RNA recognition motifs, which specifically bind to adenylate and uridylate-rich regions within the 3’-untranslated region of the target mRNA to mediate its effect. Many of the HuR target mRNAs encode proteins important for cell growth, tumorigenesis, angiogenesis, tumor inflammation, invasion and metastasis. HuR overexpression is known to correlate well with high-grade malignancy and poor prognosis in many tumor types. Thus, HuR has emerged as an attractive drug target for cancer therapy. Novel small molecule HuR inhibitors have been identified by high throughput screening and new formulations for targeted delivery of HuR siRNA to tumor cells have been developed with promising anticancer activity. This review summarizes the significant role of HuR in cancer development, progression, and poor treatment response. We will discuss the potential and challenges of targeting HuR therapeutically.
Keywords: Hu-antigen R, RNA-binding protein, 3’untranslated region, messenger RNA, mRNA stability, translation, cancer drug target.
Graphical Abstract
[2]
Mitchell, P.; Tollervey, D. mRNA stability in eukaryotes. Curr. Opin. Genet. Dev., 2000, 10(2), 193-198.
[3]
Pullmann, R., Jr; Kim, H.H.; Abdelmohsen, K.; Lal, A.; Martindale, J.L.; Yang, X.; Gorospe, M. Analysis of stability and translation regulatory RBP expression through binding to cognate mRNAs. Mol. Cell. Biol., 2007, 27(18), 6265-6278.
[4]
Keene, J.D. RNA regulons: Coordination of post-transcriptional events. Nat. Rev. Genet., 2007, 8(7), 533-543.
[5]
Valencia-Sanchez, M.A.; Liu, J.; Hannon, G.J.; Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev., 2006, 20(5), 515-524.
[6]
Brooks, S.A.; Blackshear, P.J. Tristetraprolin (TTP): Interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim. Biophys. Acta, 2013, 1829(6-7), 666-679.
[7]
Sanduja, S.; Blanco, F.F.; Dixon, D.A. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip. Rev. RNA, 2011, 2(1), 42-57.
[8]
Stoecklin, G.; Mayo, T.; Anderson, P. ARE-mRNA degradation requires the 5′-3′ decay pathway. EMBO Rep., 2006, 7(1), 72-77.
[9]
Gherzi, R.; Lee, K.Y.; Briata, P.; Wegmuller, D.; Moroni, C.; Karin, M.; Chen, C.Y. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol. Cell, 2004, 14(5), 571-583.
[10]
Vindry, C.; Vo Ngoc, L.; Kruys, V.; Gueydan, C. RNA-binding protein-mediated post-transcriptional controls of gene expression: Integration of molecular mechanisms at the 3′ end of mRNAs? Biochem. Pharmacol., 2014, 89(4), 431-440.
[11]
Ma, W.J.; Cheng, S.; Campbell, C.; Wright, A.; Furneaux, H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J. Biol. Chem., 1996, 271(14), 8144-8151.
[12]
Ma, W.J.; Furneaux, H. Localization of the human HuR gene to chromosome 19p13.2. Hum. Genet., 1997, 99(1), 32-33.
[13]
Burd, C.G.; Dreyfuss, G. Conserved structures and diversity of functions of RNA-binding proteins. Science (New York, NY.), 1994, 265(5172), 615-621.
[14]
Ma, W.J.; Chung, S.; Furneaux, H. The Elav-like proteins bind to AU-rich elements and to the poly(A) tail of mRNA. Nucleic Acids Res., 1997, 25(18), 3564-3569.
[15]
Lopez de Silanes, I.; Zhan, M.; Lal, A.; Yang, X.; Gorospe, M. Identification of a target RNA motif for RNA-binding protein HuR. Proc. Natl. Acad. Sci. USA, 2004, 101(9), 2987-2992.
[16]
Brennan, C.M.; Steitz, J.A. HuR and mRNA stability. Cell. Mol. Life Sci., 2001, 58(2), 266-277.
[17]
Abdelmohsen, K.; Kuwano, Y.; Kim, H.H.; Gorospe, M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: Implications for cellular senescence. Biol. Chem., 2008, 389(3), 243-255.
[18]
Hinman, M.N.; Lou, H. Diverse molecular functions of Hu proteins. Cell. Mol. Life Sci., 2008, 65(20), 3168-3181.
[19]
Lutz, C.S.; Moreira, A. Alternative mRNA polyadenylation in eukaryotes: An effective regulator of gene expression. Wiley Interdiscip. Rev. RNA, 2011, 2(1), 23-31.
[20]
Zhu, H.; Zhou, H.L.; Hasman, R.A.; Lou, H. Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences. J. Biol. Chem., 2007, 282(4), 2203-2210.
[21]
Halees, A.S.; El-Badrawi, R.; Khabar, K.S. ARED Organism: expansion of ARED reveals AU-rich element cluster variations between human and mouse. Nucleic Acids Res., 2008, 36(Database issue), D137-D140.
[22]
Audic, Y.; Hartley, R.S. Post-transcriptional regulation in cancer. Biol. Cell, 2004, 96(7), 479-498.
[23]
Lagnado, C.A.; Brown, C.Y.; Goodali, G.J. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol. Cell. Biol., 1994, 14(12), 7984-7995.
[24]
Abdelmohsen, K.; Gorospe, M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip. Rev. RNA, 2010, 1(2), 214-219.
[25]
Izquierdo, J.M. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J. Biol. Chem., 2008, 283(27), 19077-19084.
[26]
Chen, C.Y.; Gherzi, R.; Ong, S.E.; Chan, E.L.; Raijmakers, R.; Pruijn, G.J.; Stoecklin, G.; Moroni, C.; Mann, M.; Karin, M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell, 2001, 107(4), 451-464.
[27]
Lal, A.; Mazan-Mamczarz, K.; Kawai, T.; Yang, X.; Martindale, J.L.; Gorospe, M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J., 2004, 23(15), 3092-3102.
[28]
Young, L.E.; Moore, A.E.; Sokol, L.; Meisner-Kober, N.; Dixon, D.A. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol. Cancer Res., 2012, 10(1), 167-180.
[29]
Durie, D.; Lewis, S.M.; Liwak, U.; Kisilewicz, M.; Gorospe, M.; Holcik, M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene, 2011, 30(12), 1460-1469.
[30]
Bhattacharyya, S.N.; Habermacher, R.; Martine, U.; Closs, E.I.; Filipowicz, W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell, 2006, 125(6), 1111-1124.
[31]
Kawai, T.; Lal, A.; Yang, X.; Galban, S.; Mazan-Mamczarz, K.; Gorospe, M. Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR. Mol. Cell. Biol., 2006, 26(8), 3295-3307.
[32]
Kullman, M.; Gopfert, U.; Siewe, B.; Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5’UTR. Genes Dev., 2002, 16(23), 3087-3099.
[33]
Meng, Z.; Jackson, N.L.; Choi, H.; King, P.H.; Emanuel, P.D.; Blume, S.W. Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-1R translational control in human breast tumor cells. J. Cell. Physiol., 2008, 217(1), 172-183.
[34]
Kim, H.H.; Kuwano, Y.; Srikantan, S.; Lee, E.K.; Martindale, J.L.; Gorospe, M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev., 2009, 23(15), 1743-1748.
[35]
Abdelmohsen, K.; Srikantan, S.; Kuwano, Y.; Gorospe, M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc. Natl. Acad. Sci. USA, 2008, 105(51), 20297-20302.
[36]
Marasa, B.S.; Srikantan, S.; Martindale, J.L.; Kim, M.M.; Lee, E.K.; Gorospe, M.; Abdelmohsen, K. MicroRNA profiling in human diploid fibroblasts uncovers miR-519 role in replicative senescence. Aging (Albany N.Y.), 2010, 2(6), 333-343.
[37]
Abdelmohsen, K.; Kim, M.M.; Srikantan, S.; Mercken, E.M.; Brennan, S.E.; Wilson, G.M.; de Cabo, R.; Gorospe, M. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle, 2010, 9(7), 1354-1359.
[38]
Guo, X.; Wu, Y.; Hartley, R.S. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol., 2009, 6(5), 575-583.
[39]
Xu, F.; Zhang, X.; Lei, Y.; Liu, X.; Liu, Z.; Tong, T.; Wang, W. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J. Cell. Biochem., 2010, 111(3), 727-734.
[40]
Kojima, K.; Fujita, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate, 2010, 70(14), 1501-1512.
[41]
AL-Ahmadi. W.; Al-Ghamdi, M.; Al-Souhibani, N.; Khabar, K.S. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol., 2013, 230(1), 28-38.
[42]
Srikantan, S.; Tominaga, K.; Gorospe, M. Functional interplay between RNA-binding protein HuR and microRNAs. Curr. Protein Pept. Sci., 2012, 13(4), 372-379.
[43]
Al-Ahmadi, W.; Al-Ghamdi, M.; Al-Haj, L.; Al-Saif, M.; Khabar, K.S. Alternative polyadenylation variants of the RNA binding protein HuR: Abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Res., 2009, 37(11), 3612-3624.
[44]
Yi, J.; Chang, N.; Liu, X.; Guo, G.; Xue, L.; Tong, T.; Gorospe, M.; Wang, W. Reduced nuclear export of HuR mRNA by HuR is linked to the loss of HuR in replicative senescence. Nucleic Acids Res., 2010, 38(5), 1547-1558.
[45]
Wang, H.; Molfenter, J.; Zhu, H.; Lou, H. Promotion of exon 6 inclusion in HuD pre-mRNA by Hu protein family members. Nucleic Acids Res., 2010, 38(11), 3760-3770.
[46]
Fan, X.C.; Steitz, J.A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J., 1998, 17(12), 3448-3460.
[47]
Fan, X.C.; Steitz, J.A. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc. Natl. Acad. Sci. USA, 1998, 95(26), 15293-15298.
[48]
Gallouzi, I.E.; Brennan, C.M.; Stenberg, M.G.; Swanson, M.S.; Eversole, A.; Maizels, N.; Steitz, J.A. HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc. Natl. Acad. Sci. USA, 2000, 97(7), 3073-3078.
[49]
Doller, A. Akool El-S; Huwiler, A.; Muller, R.; Radeke, H.H.; Pfeilschifter, J.; Eberhardt, W. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol. Cell. Biol., 2008, 28(8), 2608-2625.
[50]
Doller, A.; Huwiler, A.; Muller, R.; Radeke, H.H.; Pfeilschifter, J.; Eberhardt, W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: Implications for posttranscriptional regulation of cyclooxygenase-2. Mol. Biol. Cell, 2007, 18(6), 2137-2148.
[51]
Wang, W.; Fan, J.; Yang, X.; Furer-Galban, S.; Lopez de Silanes, I.; von Kobbe, C.; Guo, J.; Georas, S.N.; Foufelle, F.; Hardie, D.G.; Carling, D.; Gorospe, M. AMP-activated kinase regulates cytoplasmic HuR. Mol. Cell. Biol., 2002, 22(10), 3425-3436.
[52]
Kim, H.H.; Gorospe, M. Phosphorylated HuR shuttles in cycles. Cell Cycle, 2008, 7(20), 3124-3126.
[53]
Kim, H.H.; Abdelmohsen, K.; Lal, A.; Pullmann, R., Jr; Yang, X.; Galban, S.; Srikantan, S.; Martindale, J.L.; Blethrow, J.; Shokat, K.M.; Gorospe, M. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev., 2008, 22(13), 1804-1815.
[54]
Abdelmohsen, K.; Pullmann, R., Jr; Lal, A.; Kim, H.H.; Galban, S.; Yang, X.; Blethrow, J.D.; Walker, M.; Shbert, J.; Gillespie, D.A.; Furneaux, H.; Gorospe, M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell, 2007, 25(4), 543-557.
[55]
Doller, A.; Schlepckow, K.; Schwalbe, H.; Pfeilschifter, J.; Eberhardt, W. Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. Mol. Cell. Biol., 2010, 30(6), 1397-1410.
[56]
Doller, A.; Pfeilschifter, J.; Eberhardt, W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell. Signal., 2008, 20(12), 2165-2173.
[57]
Amadio, M.; Bucolo, C.; Leggio, G.M.; Drago, F.; Govoni, S.; Pascale, A. The PKCβ/HuR/VEGF pathway I diabetic retinopathy. Biochem. Pharmacol., 2010, 80(8), 1230-1237.
[58]
Lafarga, V.; Cuadrado, A.; Lopez de Silanes, I.; Bengoechea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 mitogen-activated protein kinase- and HuR-dependent stabilization of p21 (Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[59]
Li, H.; Park, S.; Kilburn, B.; Jelinek, M.A.; Henschen-Edman, A.; Aswad, D.W.; Stallcup, M.R.; Laird-Offringa, I.A. Lipopolusaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM11 coactivator-associated arginiemethyltransferase. J. Biol. Chem., 2002, 277(47), 44623-45430.
[60]
Fujiwara, T.; Mori, Y.; Chu, D.; Koyama, Y.; Miyata, S.; Tanaka, H.; Yachi, K.; Kubo, T.; Yoshikawa, H.; Tohyama, M. CARM1 regulates proliferation of PC12 cells by methylating huD. Mol. Cell. Biol., 2006, 26(6), 2273-2285.
[61]
Pang, L.; Tian, H.; Chang, N.; Yi, J.; Xue, L.; Jiang, B.; Gorospe, M.; Zhang, X.; Wang, W. Loss of CARM1 is linked to reduced HuR function in replicative senescence. BMC Mol. Biol., 2013, 14, 15.
[62]
Abdelmohsen, K.; Srikantan, S.; Yang, X.; Lal, A.; Kim, H.H.; Kuwano, Y.; Galban, S.; Becker, K.G.; Kamara, D.; de Cabo, R.; Gorospe, M. Ubiquitin-mediated proteolysis of HuR by heat shock. EMBO J., 2009, 28(9), 1271-1282.
[63]
Lucchesi, C.; Sheikh, M.S.; Huang, Y. Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2. Oncogene, 2016, 35(20), 2565-2573.
[64]
Zhou, H.L.; Geng, C.; Luo, G.; Lou, H. The p97-UBXD8 complex destabilizes mRNA by promoting release of ubiquitinated HuR from mRNP. Genes Dev., 2013, 27(9), 1046-1058.
[65]
Zhou, L.; Zhang, W.; Sun, Y.; Jia, L. Protein neddylation and its alterations in human cancers for targeted therapy. Cell. Signal., 2018, 44, 92-102.
[66]
Embade, N.; Fernandez-Ramos, D.; Varlea-Rey, M.; Beraza, N.; Sini, M.; Gutierrez de Juan, V.; Woodhoo, A.; Martinez-Lopez, N.; Rodriguez-Iruretagoyena, B.; Bustamante, F.J.; de la Hoz, A.B.; Carracedo, A.; Xirodimas, D.P.; Rodriguez, M.S.; Lu, S.C.; Mato, J.M.; Martinez-Chantar, M.L. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 2012, 55(4), 1237-1248.
[67]
de Sousa, G.F. Lima, Mde, A.; Custodio, D.F.; Freitas, V.M.; Monteiro, G. Chemogenomic study of carboplatin in Saccharomyces cerevisiae: inhibition of the NEDDylation process overcomes cellular resistance mediated by HuR and Cullin proteins. PLoS One, 2015, 10(12), e0145377.
[68]
Nabors, L.B.; Gillespie, G.Y.; Harkins, L.; King, P.H. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res., 2001, 61(5), 2154-2161.
[69]
Dixon, D.A.; Tolley, N.D.; King, P.H.; Nabors, L.B.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest., 2001, 108(11), 1657-1665.
[70]
Wang, H.; Ding, N.; Guo, J.; Xia, J.; Ruan, Y. Dysregulation of TPP and HuR plays an important role in cancers. Tumour Biol., 2016, 37(11), 14451-14461.
[71]
Heinonen, M.; Bono, P.; Narko, K.; Chang, S.H.; Lundin, J.; Joensuu, H.; Furneaux, H.; Hla, T.; Haglund, C.; Ristimaki, A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res., 2005, 65(6), 2157-2161.
[72]
Lim, S.J.; Kim, H.J.; Kim, J.Y.; Park, K.; Lee, C.M. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int. J. Gynecol. Pathol., 2007, 26(3), 229-234.
[73]
Denkert, C.; Koch, I.; von Keyserkingk, N.; Noske, A.; Niesporek, S.; Dietel, M.; Weichert, W. Expression of the ELAV-like protein HuR in human colon cancer: Association with tumor stage and cyclooxygenase-2. Mod. Pathol., 2006, 19(9), 1261-1269.
[74]
Lauriola, L.; Granone, P.; Ramella, S.; Lanza, P.; Ranelletti, F.O. Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol. Histopathol., 2012, 27(5), 617-626.
[75]
Denkert, C.; Weichert, W.; Pest, S.; Koch, I.; Licht, D.; Kobel, M.; Reles, A.; Sehouli, J.; Dietel, M.; Hauptmann, S. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res., 2004, 64(1), 189-195.
[76]
Liang, P.I.; Li, W.M.; Wang, Y.H.; Wu, T.F.; Wu, W.R.; Liao, A.C.; Shen, K.H.; Wei, Y.C.; Hsing, C.H.; Shiue, Y.L.; Huang, H.Y.; Hsu, H.P.; Chen, L.T.; Lin, C.Y.; Tai, C.; Lin, C.M.; Li, C.F. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer, 2012, 12, 611.
[77]
Lopez de Silanes, I.; Lal, A.; Gorospe, M. HuR: post-transcriptional paths to malignancy. RNA Biol., 2005, 2(1), 11-13.
[78]
Mazan-Mamczarz, K.; Hagner, P.R.; Corl, S.; Srikanta, S.; Wood, W.H.; Becker, K.G.; Gorospe, M.; Kenne, J.D.; Levenson, A.S.; Gartenhaus, R.B. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene, 2008, 27(47), 6151-6163.
[79]
Malumbres, M.; Barbacid, M. Cell Cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
[80]
Ohtani, N.; Mann, D.J.; Hara, E. Cellular senescence: Its role in tumor suppression and aging. Cancer Sci., 2009, 100(5), 792-797.
[81]
Wang, W.; Yang, X.; Cristofalo, V.J.; Holbrook, N.J.; Gorospe, M. Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence. Mol. Cell. Biol., 2001, 21(17), 5889-5898.
[82]
Musgrove, E.A.; Lee, C.S.; Buckley, M.F.; Sutherland, R.L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 1994, 91(17), 8022-8026.
[83]
Hwang, H.C.; Clurman, B.E. Cyclin E in normal and neoplastic cell cycles. Oncogene, 2005, 24(17), 2776-2786.
[84]
Guo, X.; Hartley, R.S. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res., 2006, 66(16), 7948-7956.
[85]
Wang, W.; Caldwell, M.C.; Lin, S.; Furneaux, H.; Gorospe, M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J., 2000, 19(10), 2340-2350.
[86]
Kim, H.H.; Yang, X.; Kuwano, Y.; Gorospe, M. Modification at HuR (S242) alters HuR localization and proliferative influence. Cell Cycle, 2008, 7(21), 3371-3377.
[87]
Kim, H.H.; Gorospe, M. Phosphorylated HuR shuttles in cycles. Cell Cycle, 2008, 7(20), 3124-3126.
[88]
Kullmann, M.; Gopfert, U.; Siewe, B.; Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5’UTR. Genes Dev., 2002, 16(23), 3087-3099.
[89]
Wang, X.; Gorospe, M.; Huang, Y.; Holbrook, N.J. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene, 1997, 15(24), 2991-2997.
[90]
Lee, J.H.; Jung, M.; Hong, J.; Kim, M.K.; Chung, I.K. Loss of RNA-binding protein HuR facilitates cellular senescence through posttranscriptional regulation of TIN2 mRNA. Nucleic Acids Res., 2018, 46(8), 4271-4285.
[91]
Ghisolfi, L.; Calastretti, A.; Franzi, S.; Canti, G.; Donnini, M.; Capaccioli, S.; Nicolin, A.; Bevilacqua, A. B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. J. Biol. Chem., 2009, 284(31), 20946-20955.
[92]
Cui, J.; Placzek, W.J. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int. J. Mol. Sci., 2018, 19(1), 308.
[93]
Abdelmohsen, K.; Lal, A.; Kim, H.H.; Gorospe, M. Posttranscriptional orchestration of an anti-apoptosis program by HuR. Cell Cycle, 2007, 6(11), 1288-1292.
[94]
Abdelmohsen, K.; Pullmann, P., Jr; Lal, A.; Kim, H.H.; Galban, S.; Yang, X.; Blethrow, J.D.; Walker, M.; Shubert, J.; Gillespie, D.A.; Furneaux, H.; Gorospe, M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell, 2007, 25(4), 543-557.
[95]
Lafarga, V.; Cuadrado, A.; Lopez de Silanes, I.; Bengoechea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[96]
Kim, H.H.; Kuwano, Y.; Srikantan, S.; Lee, E.K.; Martindale, J.L.; Gorospe, M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev., 2009, 23(15), 1743-1748.
[97]
Wang, W.; Furneaux, H.; Cheng, H.; Caldwell, M.C.; Hutter, D.; Liu, Y.; Holbrook, N.; Gorospe, M. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell. Biol., 2000, 20(3), 760-769.
[98]
Fernau, N.S.; Fugmann, D.; Leyendecker, M.; Reimann, K.; Grether-Beck, S.; Galban, S.; Ale-Agha, N.; Krutmann, J.; Klotz, L.O. Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J. Biol. Chem., 2010, 285(6), 3896-3904.
[99]
Subbaramaiah, K.; Marmo, T.P.; Dixon, D.A.; Dannenberg, A.J. Regulation of cyclooxygenase-2 mRNA stability by taxanes: Evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem., 2003, 278(39), 37637-37647.
[100]
Lafarga, V.; Cuadrado, A.; Lopez De Silanes, I.; Bengocchea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[101]
King, F.W.; Shtivelman, E. Inhibition of nuclear import by the proapoptotic protein CC3. Mol. Cell. Biol., 2004, 24(16), 7091-7101.
[102]
Zhao, J.; Chen, J.; Lu, B.; Dong, L.; Wang, H.; Bi, C.; Wu, G.; Guo, H.; Wu, M.; Guo, Y. TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. Cancer Res., 2008, 68(11), 4133-4141.
[103]
Klotz, L.O. Reactive Oxygen Species as Initiators and Mediators of
Cellular Signaling Processes. In: Studies on Experimental Toxicology
and Pharmaology; Roberts, S.M.; Kehrer, J.P.; Klotz, L.O.,
Eds.; Humana Press. New York. 2015, pp. 149-172.
[104]
Benoit, R.M.; Meisner, N.C.; Kallen, J.; Graff, P.; Hemmig, R.; Cebe, R.; Osterneier, C.; Widner, H.; Auer, M. The x-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. J. Mol. Biol., 2010, 397(5), 1231-1244.
[105]
Levy, N.S.; Chung, S.; Furneaux, H.; Levy, A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 1998, 273(11), 6417-6423.
[106]
Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2000, 2(3), 161-174.
[107]
Deryugina, E.I.; Quigley, J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev., 2006, 25(1), 9-34.
[108]
Clark, J.C.; Thomas, D.M.; Choong, P.F.; Dass, C.R. RECK – a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev., 2007, 26(3-4), 675-683.
[109]
Akool, el-S.; Kleinert, H.; Hamada, F.M.; Abdelwahab, M.H.; Forstermann, U.; Pfeilschifter, J.; Eberhardt, W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell. Biol., 2003, 23(14), 4901-4916.
[110]
Huwiler, A. Akool, el-S.; Aschrafi, A.; Hamada, F.M.; Pfeilschifter, J.; Eberhardt, W. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J. Biol. Chem., 2003, 278(51), 51758-51769.
[111]
Mahmood, N.; Mihalcioiu, C.; Rabbani, S.A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front. Oncol., 2018, 8, 24.
[112]
Mazar, A.P. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin. Cancer Res., 2008, 14, 5649-5655.
[113]
Tran, H.; Maurer, F.; Nagamine, Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol. Cell. Biol., 2003, 23(20), 7177-7188.
[114]
D’Alessio, S.; Blasi, F. The urokinase receptor as an entertainer of signal transduction. Front. Biosci., 2009, 14, 4575-4587.
[115]
Mauro, C.D.; Pesapane, A.; Formisano, L.; Rosa, R.; D’Amato, V.; Ciciola, P.; Servetto, A.; Marciano, R.; Orsini, R.C.; Monteleone, F.; Zambrano, N.; Fontanini, G.; Servadio, A.; Pignataro, G.; Grumetto, L.; Lavecchia, A.; Bruzzese, D.; Iaccarino, A.; Troncone, G.; Veneziani, B.M.; Montuori, N.; Placido, S.; Bianco, R. Uorkinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci. Rep., 2017, 7, 9388.
[116]
Dong, R.; Lu, J.G.; Wang, Q.; He, X.L.; Chu, Y.K. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration. Biochem. Biophys. Res. Commun., 2007, 356, 318-321.
[117]
Pu, J.; Zhang, X.; Luo, H.; Xu, L.; Lu, X.; Lu, J. Adrenaline promotes epithelial-to-mesenchymal transition via HuR-TGFβ regulatory axis in pancreatic cancer cells and the implication in cancer prognosis. Biochem. Biophys. Res. Commun., 2017, 493, 1273-1279.
[118]
Kuwano, Y.; Kim, H.H.; Abdelmohsen, K.; Pullmann, R., Jr; Martindale, J.L. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol. Cell. Biol., 2008, 28, 4562-4575.
[119]
Keyse, S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 2008, 27(2), 253-261.
[120]
Wang, X.; Liu, Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell. Signal., 2007, 19(7), 1372-1382.
[121]
Bierie, B.; Moses, H.L. Tumor microenvironment: TGFbeta the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer, 2006, 6(7), 506-520.
[122]
Derynck, R.; Akhurst, R.J.; Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet., 2001, 29(2), 117-129.
[123]
Beck, C.; Schreiber, H.; Rowley, D. Role of TGF-beta in immune-evasion of cancer. Microsc. Res. Tech., 2001, 52(4), 387-395.
[124]
Torre-Amione, G.; Beauchamp, R.D.; Koeppen, H.; Park, B.H.; Schreiber, H.; Moses, H.L.; Rowley, D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 1990, 87(4), 1486-1490.
[125]
Hong, S. RNA binding protein as an emerging therapeutic target for cancer prevention and treatment. J. Cancer Prev., 2017, 22(4), 203-210.
[126]
Brennan, S.E.; Kuwano, Y.; Alkharouf, N.; Blackshear, P.J.; Gorospe, M.; Wilson, G.M. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res., 2009, 69(12), 5168-5176.
[127]
Hitti, E.; Bakheet, T.; Al-Souhibani, N.; Moghrabi, W.; Al-Yahya, S.; Al-Ghamdi, M.; Al-Saif, M.; Shoukri, M.M.; Lanczky, A.; Grepin, R.; Gyorffy, B.; Pages, G.; Khabar, K.S. Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins. Cancer Res., 2016, 76(14), 4068-4080.
[128]
Kim, I.; Kwak, H.; Lee, H.K.; Hyun, S.; Jeong, S. β-Catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3′-UTR and interacts with HuR in colon cancer cells. Nucleic Acids Res., 2012, 40(14), 6863-6872.
[129]
Ahuja, D.; Goyal, A.; Ray, P.S. Interplay between RNA-binding protein HuR and microRNA-125b regulates p53 mRNA translation in response to genotoxic stress. RNA Biol., 2016, 13(11), 1152-1165.
[130]
Poria, D.K.; Guha, A.; Nandi, I.; Ray, P.S. RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4. Oncogene, 2016, 35(13), 1703-1715.
[131]
Gunzburg, M.J.; Sivakumaran, A.; Pendini, N.R.; Yoon, J.H.; Gorospe, M.; Cj Wilce, M.; Wilce, J.A. Cooperative interplay of let-7 mimic and HuR with MYC RNA. Cell Cycle, 2015, 14(17), 2729-2733.
[132]
Kundu, P.; Fabian, M.R.; Sonenberg, N.; Bhattacharyya, S.N.; Filipowicz, W. HuR protein attenuates miRNA-mediated repression by promoting miRISC disccoiation from the target RNA. Nucleic Acids Res., 2012, 40(11), 5088-5100.
[133]
Kotta-Loizou, I.; Giaginis, C.; Theocharis, S. Clinical significance of HuR expression in human malignancy. Med. Oncol., 2014, 31(9), 161.
[134]
Wang, J.; Guo, Y.; Chu, H.; Guan, Y.; Bi, J.; Wang, B. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int. J. Mol. Sci., 2013, 14(5), 10015-10041.
[135]
Zucal, C.; D’Agostino, V.; Loffredo, R.; Mantelli, B.; Natthakan, T.; Lal, P.; Latorre, E.; Provenzani, A. Targeting the multifaceted HuR protein, benefits and caveats. Curr. Drug Targets, 2015, 16(5), 499-515.
[136]
Blanco, F.F.; Jimbo, M.; Wulfkuhle, J.; Gallagher, I.; Deng, J.; Enyenihi, L.; Meisner-Kober, N.; Londin, E.; Rigoutsos, I.; Sawicki, J.A.; Risbud, M.V.; Witkiewicz, A.K.; McCue, P.A.; Jiang, W.; Rui, H.; Yeo, C.J.; Petricoin, E.; Winter, J.M.; Brody, J.R. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene, 2016, 35(19), 2529-2541.
[137]
McAllister, F.; Pineda, D.M.; Jimbo, M.; Lal, S.; Burkhart, R.A.; Moughan, J.; Winter, K.A.; Abdelmohsen, K.; Gorospe, M.; de Jesus Acosta, A.; Lankapalli, R.H.; Winter, J.M.; Yeo, C.J.; Witkiewicz, A.K.; Iacobuzio-Donahue, C.A.; Laheru, D.; Brody, J.R. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biol. Ther., 2014, 15(6), 688-698.
[138]
Pineda, D.M.; Rittenhouse, D.W.; Valley, C.C.; Cozzitorto, J.A.; Burkhart, R.; Leiby, B.; Winter, J.M.; Weber, M.C.; Londin, E.R.; Rigoutsos, I.; Yeo, C.J.; Gorospe, M.; Witkiewicz, A.K.; Sachs, J.N.; Brody, J.R. HuR’s post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biol. Ther., 2012, 13(10), 946-955.
[139]
Richards, N.G.; Rittenhouse, D.W.; Freydin, B.; Cozzitorto, J.A.; Grenda, D.; Rui, H.; Gonye, G.; Kennedy, E.P.; Yeo, C.J.; Brody, J.R.; Witkiewicz, A.K. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg., 2010, 252(3), 499-505.
[140]
Costantino, C.L.; Witkiewicz, A.K.; Kuwano, Y. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res., 2009, 69(11), 4567-4572.
[141]
Tatarian, T.; Jiang, W.; Leiby, B.E.; Grigoli, A.; Jimbo, M.; Dabbish, N.; Neoptolemos, J.P.; Greenhalf, W.; Costello, E.; Ghaneh, P.; Halloran, C.; Palmer, D.; Buchler, M.; Yeo, C.J.; Winter, J.M.; Brody, J.R. Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer. Ann. Surg., 2018, 267(2), 364-369.
[142]
Vigouroux, C.; Casse, J.M.; Battaglia-Hsu, S.F.; Brochin, L.; Luc, A.; Paris, C.; Lacomme, S.; Gueant, J.L.; Vignaud, J.M.; Gauchotte, G. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma. Lung Cancer, 2015, 89(2), 189-196.
[143]
Lal, S.; Burkhart, R.A.; Beeharry, N.; Bhattacharjee, V.; Londin, E.R.; Cozzitorto, J.A.; Romeo, C.; Jimbo, M.; Norris, Z.A.; Yeo, C.J.; Sawicki, J.A.; Winter, J.M.; Rigoutsos, I.; Yen, T.J.; Brody, J.R. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells. Cancer Res., 2014, 74(4), 1128-1140.
[144]
Jimbo, M.; Blanco, F.F.; Huang, Y.H.; Telonis, A.G.; Screnci, B.A.; Cosma, G.L.; Alexeev, V.; Gonye, G.E.; Yeo, C.J.; Sawicki, J.A.; Winter, J.M.; Brody, J.R. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6(29), 27312-27331.
[145]
Magnuson, N.S.; Wang, Z.; Ding, G.; Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol., 2010, 6(9), 1461-1478.
[146]
Chand, S.N.; Zarei, M.; Schiewer, M.J.; Kamath, A.R.; Romeo, C.; Lal, S.; Cozzitorto, J.A.; Nevler, A.; Scolaro, L.; Londin, E.; Jiang, W.; Meisner-Kober, N.; Pishvaian, M.J.; Knudsen, K.E.; Yeo, C.J.; Pascal, J.M.; Winter, J.M.; Brody, J.R. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Res., 2017, 77(18), 5011-5025.
[147]
Zarei, M.; Lal, S.; Parker, S.J.; Nevler, A.; Vaziri-Gohar, A.; Dukleska, K.; Mambelli-Lisboa, N.C.; Moffat, C.; Blanco, F.F.; Chand, S.N.; Jimbo, M.; Cozzitorto, J.A.; Jiang, W.; Yeo, C.J.; Londin, E.R.; Seifert, E.L.; Metallo, C.M.; Brody, J.R.; Winter, J.M. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res., 2017, 77(16), 4460-4471.
[148]
Jakstaite, A.; Maziukiene, A.; Silkuniene, G.; Kmieliute, K.; Gulbinas, A.; Dambrauskas, Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J. Gastroenterol., 2018, 21(46), 13004-13019.
[149]
Satoh, K.; Kaneko, K.; Hirota, M.; Masamune, A.; Satoh, A.; Shimosegawa, T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas, 2001, 23(3), 251-258.
[150]
Romeo, C.; Weber, M.C.; Zarei, M.; DeCicco, D.; Chand, S.N.; Lobo, A.D.; Winter, J.M.; Sawicki, J.A.; Sachs, J.N.; Meisner-Kober, N.; Yeo, C.J.; Vadigepalli, R.; Tykocinski, M.L.; Bridy, J.R. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol. Cancer Res., 2016, 14(7), 599-611.
[151]
To, K.K.; Leung, W.W.; Ng, S.S. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp. Cell Res., 2015, 338(2), 222-231.
[152]
Badawi, A.; Biyanee, A.; Nasrullah, U.; Winslow, S.; Schmid, T.; Pfeilschifter, J.; Eberhardt, W. Inhibition of IRES-dependent translation of caspase-2 by HuR confers chemotherapeutic drug resistance in colon carcinoma cells. Oncotarget, 2018, 9(26), 18367-18385.
[153]
Bonzon, C.; Bouchier-Hayes, L.; Pagliari, L.J.; Green, D.R.; Newmeyer, D.D. Caspase-2-induced apoptosis requires bid cleavage: A physiological role for bid in heat shock-induced death. Mol. Biol. Cell, 2006, 17(5), 2150-2157.
[154]
Von Roretz, C.; Lian, X.J.; Macri, A.M.; Punjani, N.; Clair, E.; Drouin, O.; Dormoy-Raclet, V.; Ma, J.F.; Gallouzi, I.E. Apoptotic-induced cleavage shifts HuR from being a promoter of survival to an activator of caspase-mediated apoptosis. Cell Death Differ., 2013, 20(1), 154-168.
[155]
Janakiraman, H.; House, R.P.; Talwar, S.; Courtney, S.M.; Hazard, E.S.; Hardiman, G.; Mehrotra, S.; Howe, P.H.; Gangaraju, V.; Palanisamy, V. Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene, 2017, 36(22), 3137-3148.
[156]
Zhou, Y.; Chang, R.; Ji, W.; Wang, N.; Qi, M.; Xu, Y.; Guo, J.; Zhan, L. Loss of scribble promotes Snail translation through translocation of HuR and enhances cancer drug resistance. J. Biol. Chem., 2016, 291(1), 291-302.
[157]
Ghosh, M.; Aguila, H.L.; Michaud, J.; Ai, Y.; Wu, M.T.; Hemmes, A.; Ristimaki, A.; Guo, C.; Furneaux, H.; Hla, T. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J. Clin. Invest., 2009, 119(12), 3530-3543.
[158]
Katsanou, V.; Milatos, S.; Yiakouvaki, A.; Sgantzis, N.; Kotsoni, A.; Alexiou, M.; Harokopos, V.; Aidinis, V.; Hemberger, M.; Kontoyiannia, D.L. The RNA-binding protein Elav1/HuR is essential for placental branching morphogenesis and embryonic development. Mol. Cell. Biol., 2009, 29(10), 2762-2776.
[159]
Estep, J.A.; Sternburg, E.L.; Sanchez, G.A.; Karginov, F.V. Immunoblot screening of CRISPR/Cas9-mediated gene knockouts without selection. BMC Mol. Biol., 2016, 17, 9.
[160]
Giammanco, A.; Blanc, V.; Montenegro, G.; Klos, C.; Xie, Y.; Kennedy, S.; Luo, J.; Chang, S.H.; Hla, T.; Nalbantoglu, I.; Dharmarajan, S.; Davidson, N.O. Intestinal epithelial HuR modulates distinct pathways of proliferation and apoptosis and attenuates small intestinal and colonic tumor development. Cancer Res., 2014, 74(18), 5322-5335.
[161]
Yiakouvaki, A.; Dimitriou, M.; Karakasiliotis, I.; Eftychi, C.; Theocharis, S.; Kontoyiannis, D.L. Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J. Clin. Invest., 2012, 122(1), 48-61.
[162]
Weiss, W.A.; Taylor, S.S.; Shokat, K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol., 2007, 3(12), 739-744.
[163]
Wang, H.; Zeng, F.; Liu, Q.; Liu, H.; Liu, Z.; Niu, L.; Teng, M.; Li, X. The structure of the ARE-binding domains of Hu Antigen R (HuR) undergoes conformational changes during RNA binding. Acta Crystallogr. Sect. D: Biol. Crystallogr., 2013, 69(Pt 3), 373-380.
[164]
Scheiba, R.M.; de-Opakua, A.L.; Diaz-Quintana, A.; Cruz-Gallardo, L.; Martinez-Chantar, M.L.; Blanco, F.J.; Diaz-Moreno, I. The C-terminal RNA binding motif of HuR is a multi-functional domain leading to HuR oligomerization and binding to U-rich RNA targets. RNA Biol., 2014, 11(10), 1250-1261.
[165]
Diaz-Quintana, A.; Garcia-Maurino, S.M.; Diaz-Moreno, I. Dimerization model of the C-terminal RNA recognition motif of HuR. FEBS Lett., 2015, 589(10), 1059-1066.
[166]
Meisner, N.C.; Hintersteiner, M.; Mueller, K.; Bauer, R.; Seifert, J.M.; Naegeli, H.C.; Ottl, J.; Oberer, L.; Guenat, C.; Moss, S.; Harrer, N.; Woisetchlaeger, M.; Buehler, C.; Uhl, V.; Auer, M. Identification and mechanistic characterization of low-molecular weight inhibitors of HuR. Nat. Chem. Biol., 2007, 3(8), 508-515.
[167]
Chae, M.J.; Sung, H.Y.; Kim, E.H.; Lee, M.; Kwak, H.; Chae, C.H.; Kim, S.; Park, W.Y. Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp. Mol. Med., 2009, 41(11), 824-831.
[168]
Kwak, H.; Jeong, K.C.; Chae, M.J.; Kim, S.Y.; Park, W.Y. Flavonoids inhibit the AU-rich element binding of HuC. BMB Rep., 2009, 41(1), 41-46.
[169]
D’Agostino, V.G.; Adami, V.; Provenzani, A. A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. PLoS One, 2013, 8(8), e72426.
[170]
Wang, Z.; Bhattacharya, A.; Ivanov, D.N. Identification of small-molecule inhibitors of the HuR/RNA interaction using a fluorescence polarization screening assay followed by NMR validation. PLoS One, 2015, 10(9), e0138780.
[171]
Wu, X.; Lan, L.; Wilson, D.M.; Marquez, R.T.; Tsao, W.C.; Gao, P.; Roy, A.; Turner, B.A.; McDonald, P.; Tunge, J.A.; Rogers, S.A.; Dixon, D.A.; Aube, J.; Xu, L. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem. Biol., 2015, 10(6), 1476-1484.
[172]
D’Agostino, V.G.; Lal, P.; Mantelli, B.; Tiedje, C.; Zucal, C.; Thongon, N.; Gaestel, M.; Latorre, E.; Marinelli, L.; Seneci, P.; Amadio, M.; Provenzani, A. Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. Sci. Rep., 2015, 5, 16478.
[173]
Lal, P.; Cerofolini, L.; D’Agostino, V.G.; Zucal, C.; Fuccio, C.; Bonomo, L.; Dassi, E.; Giuntini, S.; Di Maio, D.; Vishwakarma, V.; Preet, R.; Williams, S.N.; Fairlamb, M.S.; Munk, R.; Lehrmann, E.; Abdelmohsen, K.; Elezgarai, S.R.; Luchinat, C.; Novellino, E.; Quattrone, A.; Biasini, E.; Manzoni, L.; Gorospe, M.; Dixon, D.A.; Seneci, P.; Marinelli, L.; Fragai, M.; Provenzani, A. Regulation of HuR structure and function by dihydrotanshinone-I. Nucleic Acids Res., 2017, 45(16), 9514-9527.
[174]
Kaur, K.; Wu, X.; Fields, J.K.; Johnson, D.K.; Lan, L.; Pratt, M.; Somoza, A.D.; Wang, C.C.C.; Karanicolas, J.; Oakley, B.R. Xu, l.; De Guzman, R.N. The fungal natural product azaphilone-9 binds to HuR and inhibits HuR-RNA interaction in vitro. PLoS One, 2017, 12(4), e0175471.
[175]
Manzoni, L.; Zucal, C.; Di Maio, D.; D’Agostino, V.G.; Thongon, N.; Bonomo, I.; Lal, P.; Miceli, M.; Baj, V.; Brambilla, M.; Cerofolini, L.; Elezgarai, S.; Biasini, E.; Luchinat, C.; Novellino, E.; Fragai, M.; Marinelli, L.; Provenzani, A.; Seneci, P. Interfering with HuR-RNA interaction: Design, synthesis and biological characterization of tanshinone mimics as novel, effective HuR inhibitors. J. Med. Chem., 2018, 61(4), 1483-1498.
[176]
Muralidharan, R.; Mehta, M.; Ahmed, R.; Roy, S.; Xu, L.; Aube, J.; Chen, A.; Zhao, Y.D.; Herman, T.; Ramesh, R.; Munshi, A. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci. Rep., 2017, 7(1), 9694.
[177]
Nasti, R.; Rossi, D.; Amadio, M.; Pascale, A.; Unver, M.Y.; Hirsch, A.K.H.; Collina, S. Compounds interfering with Embryonic Lethal Abnormal Vision (ELAV) protein-RNA complexes: An avenue for discovering new drugs. J. Med. Chem., 2017, 60(20), 8257-8267.
[178]
Blanco, F.F.; Preet, R.; Aguado, A.; Vishwakarma, V.; Stevens, L.E.; Vyas, A.; Padhye, S.; Xu, L.; Weir, S.J.; Anant, S.; Meisner-Kober, N.; Brody, J.R.; Dixon, D.A. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7(45), 74043-74058.
[179]
Lang, M.; Berry, D.; Passecker, K.; Mesteri, I.; Bhuju, S.; Ebner, F.; Sedlyarov, V.; Evstatiev, R.; Dammann, K.; Loy, A.; Kuzyk, O.; Kovarik, P.; Khare, V.; Beibel, M.; Roma, G.; Meisner-Kober, N.; Gasche, C. HuR small-molecule inhibitor elicits differential effects in adenomatosis polyposis and colorectal carcinogenesis. Cancer Res., 2017, 77(9), 2424-2438.
[180]
Guo, J.; Lv, L.; Chang, S.; Chen, Z.; Lu, W.; Xu, C.; Liu, M.; Pang, X. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget, 2016, 7(29), 45249-45262.
[181]
Li, B.; Flaveny, C.A.; Giambelli, C.; Fei, D.L.; Han, L.; Hang, B.I.; Bai, F.; Pei, X.H.; Nose, V.; Burlingame, O.; Capobianco, A.J.; Orton, D.; Lee, E.; Robbins, D.J. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One, 2014, 9(7), e101969.
[182]
Lim, M.; Otto-Duessel, M.; He, M.; Su, L.; Nguyen, D.; Chin, E.; Alliston, T.; Jones, J.O. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium. ACS Chem. Biol., 2014, 9(3), 692-702.
[183]
Sugimoto, K.; Hayakawa, F.; Shimada, S.; Morishita, T.; Shimada, K.; Katakai, T.; Tomita, A.; Kiyoi, H.; Naoe, T. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci. Rep., 2015, 5, 13054.
[184]
Xu, W.; Lacerda, L.; Debeb, B.G.; Atkinson, R.L.; Solley, T.N.; Li, L.; Orton, D.; McMurray, J.S.; Hang, B.I.; Lee, E.; Klopp, A.H.; Ueno, N.T.; Reuben, J.M.; Krishnamurthy, S.; Woodward, W.A. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One, 2013, 8(8), e71508.
[185]
Muralidharan, R.; Babu, A.; Amreddy, N.; Srivastava, A.; Chen, A.; Zhao, Y.D.; Kompella, U.B.; Munshi, A.; Ramesh, R. Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol. Cancer Ther., 2017, 16(8), 1470-1486.
[186]
Muralidharan, R.; Babu, A.; Amreddy, N.; Basalingappa, K.; Mehta, M.; Chen, A.; Zhao, Y.D.; Kompella, U.B.; Munshi, A.; Ramesh, R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J. Nanobiotechnology, 2016, 14(1), 47.
[187]
Huang, Y.H.; Peng, W.; Furuuchi, N.; Gerhart, J.; Rhodes, K.; Mukherjee, N.; Jimbo, M.; Gonye, G.E.; Brody, J.R.; Getts, R.C.; Sawicki, J.A. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res., 2016, 76(6), 1549-1559.
[188]
Muralidharan, R.; Panneerselvam, J.; Chen, A.; Zhao, Y.D.; Munshi, A.; Ramesh, R. HuR-targeted nanotherapy in combination with AMD3100 suppress CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther., 2015, 22, 581-590.
[189]
Lin, G.L.; Ting, H.J.; Tseng, T.C.; Juang, V.; Lo, Y.L. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS One, 2017, 12(10), e0185625.
[190]
Brody, J.R.; Gonye, G.E. HuR’s rule in gemcitabine efficacy: an exception or opportunity? Wiley Interdisc. Rev, 2011, 2(3), 435-444.
[191]
Lebedeva, S.; Jens, M.; Theil, K.; Schwanhausser, B.; Selbach, M.; Landthaler, M.; Rajewsky, N. Transcriptiome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol. Cell, 2011, 43(3), 340-352.
[192]
Mukherjee, N.; Corcoran, D.L.; Nusbaum, J.D.; Reid, D.W.; Georgiev, S.; Hafner, M.; Ascano, M., Jr; Tuschl, T.; Ohler, U.; Keene, J.D. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol. Cell, 2011, 43(3), 327-339.
[193]
Kishore, S.; Jaskiewicz, L.; Burger, L.; Hausser, J.; Khorshid, M.; Zavolan, M. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat. Methods, 2011, 8(7), 559-564.
[194]
Abdelmohsen, K.; Lal, A.; Kim, H.H.; Gorospe, M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle, 2007, 6(11), 1288-1292.
[195]
Ishimaru, D.; Ramalingam, S.; Sengupta, T.K.; Bandyopadhyay, S.; Dellis, S.; Tholanikunnel, B.G.; Fernandes, D.J.; Spicer, E.E.K. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol. Cancer Res., 2009, 7(8), 1354-1366.
[196]
Wang, J.; Zhao, W.; Guo, Y.; Zhang, B.; Xie, Q.; Xiang, D.; Gao, J.; Wang, B.; Chen, Z. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology, 2009, 76(6), 420-429.
[197]
Giles, K.M.; Daly, J.M.; Beveridge, D.J.; Thomson, A.M.; Voon, D.C.; Furneaux, H.M.; Jazayeri, J.A.; Leedman, P.J. The 3-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J. Biol. Chem., 2003, 278(5), 2937-2946.
[198]
Yuan, Z.; Sanders, A.J.; Ye, L.; Wang, Y.; Jiang, W.G. Prognostic value of the human antigen R (HuR) in human breast cancer: High level predicts a favorable prognosis. Anticancer Res., 2011, 31(1), 303-310.
[199]
Luo, N.A.; Qu, Y.Q.; Yang, G.D.; Wang, T.; Li, R.L.; Jia, L.T.; Dong, R. Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer. Int. J. Mol. Sci., 2014, 15(11), 20306-20320.
[200]
Suswan, E.A. nabors, L.B.; Huang, Y.; Yang, X.; King, P.H. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′-untranslated region: Involvement of divergent RNA-binding factors HuR, KSPR and TIAR. Int. J. Cancer, 2005, 113(6), 911-919.
[201]
Woo, H.H.; Zhou, Y.; Yi, X.; David, C.L.; Zheng, W.; Gilmore-Hebert, M.; Kluger, H.M.; Ulukus, E.C.; Baker, T.; Stoffer, J.B. Chambers, S.K. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene, 2009, 28(9), 1176-1186.
[202]
Topisirovic, I.; Siddiqui, N.; Orolicki, S.; Skrabanek, L.A.; Tremblay, M.; Hoang, T.; Borden, K.L. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and its activity is dysregulated in cancer. Mol. Cell. Biol., 2009, 29(5), 1152-1162.
[203]
Del Vecchio, G.; De Vito, F.; Saunders, S.J.; Risi, A.; Mannironi, C.; Bozzoni, I.; Presutti, C. RNA-binding protein HuR and the members of the miR-200 family play an unconventional role in the regulation of c-Jun mRNA. RNA, 2016, 22(10), 1510-1521.
[204]
Hostetter, C.; Licata, L.A.; Witkiewicz, A.; Costantino, C.L.; Yeo, C.J.; Brody, J.R.; Kenn, J.C. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol. Ther., 2008, 7(9), 1496-1506.
[205]
Feng, X.; Shikama, Y.; Shichishima, T.; Noji, H.; Ikeda, K.; Ogawa, K.; Kimura, H.; Takeishi, Y.; Kimura, J. Impairment of FOS mRNA stabilization following translation arrest in granulocytes from myelodysplastic syndrome patients. PLoS One, 2013, 8(4), e61107.
[206]
Li, Y.; Yu, J.; Du, D.; Fu, S.; Chen, Y.; Yu, F.; Gao, P. Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol. Lett., 2013, 6(1), 156-160.
[207]
Licata, L.A.; Hostetter, C.L.; Crismale, J.; Sheth, A.; Keen, J. C. The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res. Treat., 2010, 122(1), 55-63.
[208]
Sheflin, L.G.; Zou, A.P.; Spaulding, S.W. Androgens regulate the binding of endogenous HuR to the AU-rich 3’UTRs of HIF-1alpha and EGF mRNA. Biochem. Biophys. Res. Commun., 2004, 322(2), 644-651.
[209]
Yang, F.; Miao, L.; Mei, Y.; Wu, M. Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell. Signal., 2013, 25(6), 1476-1485.
[210]
Heinonen, M.; Hemmes, A.; Salmenkivi, K.; Abdelmohsen, K.; Vilen, S.T.; Laakso, M.; Leidenius, M.; Salo, T.; Hautaniemi, S.; Gorospe, M.; Heikkila, P.; Haglund, C.; Ristimaki, A. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J. Pathol., 2011, 224(4), 529-539.
[211]
Zhu, Z.; Wang, B.; Bi, J.; Zhang, C.; Guo, Y.; Chu, H.; Liang, X.; Zhong, C.; Wang, J. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol., 2013, 34(4), 2299-2308.
[212]
Heinonen, M.; Fagerholm, R.; Aaltonen, K.; Kilpivaara, O.; Aittomaki, K.; Blomqvist, C.; Heikkila, P.; Haglund, C.; Nevanlinna, H.; Ristimaki, A. Prognostic role of HuR in hereditary breast cancer. Clin. Cancer Res., 2007, 13(23), 6959-6963.
[213]
Saunus, J.M.; French, J.D.; Edwards, S.L.; Beveridge, D.J.; Hatchell, E.C.; Wagner, S.A.; Stein, S.R.; Davidson, A.; Simpson, K.J.; Francis, G.D.; Leedman, P.J.; Brown, M.A. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res., 2008, 68(22), 9469-9478.
[214]
Giaginis, C.; Sampani, A.; Kotta-Loizou, I.; Giannopoulou, I.; Danas, E.; Politi, E.; Tsourouflis, G.; Kouraklis, G.; Patsouris, E.; Keramopoulos, A.; Nakopoulou, L.; Theocharis, S. Elevated Hu-antigen receptor (HuR) expression is associated with tumor aggressiveness and poor prognosis but not with COX-2 expression in invasive breast carcinoma patients. Pathol. Oncol. Res., 2018, 24(3), 631-640.
[215]
Zhang, C.; Xue, G.; Bi, J.; Geng, M.; Chu, H.; Guan, Y.; Wang, J.; Wang, B. Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma. Tumour Biol., 2014, 35(1), 73-80.
[216]
Sun, D.P.; Lin, C.Y.; Tian, Y.F.; Chen, L.T.; Lin, L.C.; Lee, S.W.; Hsing, C.H.; Lee, H.H.; Shiue, Y.L.; Huang, H.Y.; Li, C.F.; Liang, P.I. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol., 2013, 34(5), 3059-3069.
[217]
Wei, Y.C.; Chou, F.F.; Li, C.F.; Li, W.M.; Chen, Y.Y.; Lan, J.; Li, S.H.; Fang, F.M.; Hu, T.H.; Yu, S.C.; Eng, H.L.; Uen, Y.H.; Tian, Y.F.; Wang, J.C.; Huang, H.Y. HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs). Histopathology, 2013, 63(4), 445-454.
[218]
Gauchotte, G.; Hergalant, S.; Vigouroux, C.; Casse, J.M.; Houlgatte, R.; Kaoma, T.; Helle, D.; Brochin, L.; Rech, F.; Peyre, M.; Labrousse, F.; Vallar, L.; Gueant, J.L.; Vignaud, J.M.; Battaglia-Hsu, S.F. Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia. J. Pathol., 2017, 242(4), 421-434.
[219]
Cha, J.D.; Kim, H.K.; Cha, I.H. Cytoplasmic HuR expression: Correlation with cellular inhibitors of apoptosis protein-2 expression and clinicopathologic factors in oral squamous cell carcinoma cells. Head Neck, 2014, 36(8), 1168-1175.
[220]
Kim, K.Y.; Li, S.; Cha, J.D.; Zhang, X.; Cha, I.H. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck, 2012, 34(7), 929-936.
[221]
Davidson, B.; Holth, A.; Hellesylt, E.; Hadar, R.; Katz, B.; Trope, C.G.; Reich, R. HuR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. Hum. Pathol., 2016, 48, 95-101.
[222]
Giaginis, C.; Alexandrou, P.; Delladetsima, I.; Karavokyros, I.; Danas, E.; Giagini, A.; Patsouris, E.; Theocharis, S. Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions. Pathol. Oncol. Res., 2016, 22(1), 189-196.
[223]
Liang, P.I.; Li, W.M.; Wang, Y.H.; Wu, T.F.; Wu, W.R.; Liao, A.C.; Shen, K.H.; Wei, Y.C.; Hsing, C.H.; Shiue, Y.L.; Haung, H.Y.; Hsu, H.P.; Chen, L.T. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer, 2012, 12, 611.
[224]
Sun, L.; Zhang, S.; Jiang, Z.; Huang, X.; Wang, T.; Huang, X.; Li, H.; Zhang, L. Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-a-treated A549 cells. Biochem. Biophys. Res. Commun., 2011, 416(1-2), 99-105.
[225]
Cheng, Y.C.; Liou, J.P.; Kuo, C.C.; Lai, W.Y.; Shih, K.H.; Chang, C.Y.; Pan, W.Y.; Tseng, J.T.; Chang, J.Y. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1a mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Cancer Ther., 2013, 12(7), 1202-1212.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
150
19
3